{"protocolSection":{"identificationModule":{"nctId":"NCT01107444","orgStudyIdInfo":{"id":"11766"},"secondaryIdInfos":[{"id":"H8Z-MC-JACW","type":"OTHER","domain":"Eli Lilly and Company"},{"id":"2009-017591-24","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer","officialTitle":"A Randomized Phase 2 Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Were Previously Treated With First Line Chemotherapy"},"statusModule":{"statusVerifiedDate":"2019-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-05"},"primaryCompletionDateStruct":{"date":"2011-12","type":"ACTUAL"},"completionDateStruct":{"date":"2012-06","type":"ACTUAL"},"studyFirstSubmitDate":"2010-04-15","studyFirstSubmitQcDate":"2010-04-20","studyFirstPostDateStruct":{"date":"2010-04-21","type":"ESTIMATED"},"resultsFirstSubmitDate":"2019-03-11","resultsFirstSubmitQcDate":"2019-05-02","resultsFirstPostDateStruct":{"date":"2019-05-24","type":"ACTUAL"},"dispFirstSubmitDate":"2012-05-24","dispFirstSubmitQcDate":"2012-05-24","dispFirstPostDateStruct":{"date":"2012-06-01","type":"ESTIMATED"},"lastUpdateSubmitDate":"2019-08-28","lastUpdatePostDateStruct":{"date":"2019-09-11","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the anti-tumor activity of LY2181308 in combination with docetaxel compared to docetaxel alone in participants with non-small cell lung cancer who were previously treated with first line chemotherapy."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":180,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"LY2181308 + Docetaxel","type":"EXPERIMENTAL","description":"LY2181308: 750 milligrams (mg), intravenous (IV), on Day -2 and Day -1 of a 2 day lead-in period; on Day 1, Day 6, and Day 14 for Cycle 1 (1 cycle = 21 days); and once weekly for Days 1 through 21 for Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.\n\nDocetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV), on Day 1 of Cycle 1 (1 cycle = 21 days) and on Day 1 of Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.","interventionNames":["Drug: Docetaxel","Drug: LY2181308"]},{"label":"Docetaxel","type":"ACTIVE_COMPARATOR","description":"Docetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV) on Day 1 of Cycles 1 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.","interventionNames":["Drug: Docetaxel"]}],"interventions":[{"type":"DRUG","name":"Docetaxel","description":"Administered intravenously","armGroupLabels":["Docetaxel","LY2181308 + Docetaxel"]},{"type":"DRUG","name":"LY2181308","description":"Administered intravenously","armGroupLabels":["LY2181308 + Docetaxel"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline in Tumor Size to the End of Cycle 2","description":"The tumor size was defined as the sum of the longest diameters for the target lesions. The sum of lesion diameters was calculated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines. The log ratio of tumor size at the end of Cycle 2 to tumor size at baseline was calculated for each participant.","timeFrame":"Baseline, End of Cycle 2 (1 cycle = 21 days)"}],"secondaryOutcomes":[{"measure":"Number of Participants With Characterization of Toxicities as Defined by Common Terminology Criteria for Adverse Events (CTCAE) Coding","description":"Safety analyses included listings and/or summaries of the following:\n\n1. CTCAE for laboratory and non-laboratory parameters possibly related to study drug;\n2. CTCAE Grades 3 and 4 for laboratory and non-laboratory parameters possibly related to study drug (Grade 3 - severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care. Grade 4 - life-threatening consequences; urgent intervention indicated);\n3. Dose adjustments due to adverse events (AEs).","timeFrame":"Randomization through long-term follow up (up to 21.6 months)"},{"measure":"Progression Free Survival (PFS)","description":"Progression Free Survival (PFS) was defined as the time from date of first dose to the first observation of disease progression or death due to any cause. PFS time was censored at the date of the last assessment visit for participants who were still alive and who did not have documented progressive disease as of the data cut-off date.","timeFrame":"Randomization to the first date of progressive disease or death from any cause (up to 12.88 months)"},{"measure":"Pharmacokinetics: Area Under the Concentration Curve From Zero to 4 Hours (AUC[0-4]) for LY2181309 and Docetaxel","description":"Pharmacokinetics: Area Under the Concentration Curve From Zero to 4 hours (AUC\\[0-4\\]) for LY2181309 and Docetaxel","timeFrame":"Docetaxel: Cycle(C)1 Day(D)1:0,1,1.25,1.75,3,4 hours(h);LY2181308 + Docetaxel: C1 D-1:3,4 h;D1:0,3,4 h"},{"measure":"Pharmacokinetics: Area Under the Drug Concentration-Time Curve From Zero to Infinity (AUC[0 ∞]) of LY2181309 and Docetaxel","description":"Pharmacokinetics: Area Under the Drug Concentration-Time Curve From Zero to Infinity (AUC\\[0 ∞\\]) of LY2181309 and Docetaxel","timeFrame":"Docetaxel: Cycle(C)1 Day(D)1:0,1,1.25,1.75,3,4,5,505,513,2521 hours(h);LY2181308 + Docetaxel: C1 D -1:3,4 h;D1:0,3,4,5,5.25,5.75,7,8,120,504,507,509,1008,1512,1515,1517,2016, 2520,2523,2525 h"},{"measure":"Overall Survival (OS)","description":"Overall survival (OS) was the duration from enrollment to death from any cause. For participants who were alive, OS is censored at the date of last contact.","timeFrame":"Randomization to date of death from any cause (up to 21.6 months)"},{"measure":"Time to Worsening of Symptoms as Defined by Lung Cancer Symptom Score (LCSS) Questionnaire","description":"The worsening of symptoms was defined as a 15-millimeter (mm) increase in any 1 symptom on the LCSS. The LCSS is an assessment used to evaluate 6 major symptoms associated with lung malignancies and their effect on overall symptomatic distress, functional activities, and global quality of life. LCSS consists of 2 scales: 1 completed by the participant and 1 completed by the health care professional (which is the average symptom burden index \\[ASBI\\]). Participant-reported outcomes are assessed using 9 visual analog scales (100-mm horizontal line). Participants indicate intensity of response to the items in question (0 = lowest rating, 100 = highest rating). The LCSS total score ranges from 0 (lowest rating) to 100 (highest rating). The LCSS total score was defined as the mean over all 9 items. Time to worsening of symptoms was censored at the date of the last assessment visit for participants who did not experience any worsening of symptoms as of the data cut-off date.","timeFrame":"Baseline to the worsening of symptoms (up to 4.6 months)"},{"measure":"Time to Objective Tumor Response of Partial Response (PR) or Complete Response (CR)","description":"Time to objective tumor response was defined as the time from the date of randomization to the first date of documented objective tumor response. Time to objective tumor response was censored at the date of the last assessment visit for participants who had not had documented response as of the data cut-off date. Complete response (CR) was defined as the disappearance of all target lesions; partial response (PR) was defined as at least a 30% decrease in sum of the longest diameter of target lesions.","timeFrame":"Randomization to the date of first response (up to 12.1 months)"},{"measure":"Time to Documented Disease Progression","description":"Time to documented disease progression was defined as the time from the date of randomization to the first date of documented progression. Progressive disease (PD) was defined as at least a 20% increase in sum of longest diameter of target lesions. Time to documented disease progression was censored at the date of the last assessment visit for participants who had not had documented progressive disease as of the data cut-off date.","timeFrame":"Randomization to the first date of progressive disease (up to 12.9 months)"},{"measure":"Percent of Participants Having a Partial Response (PR) or a Complete Response (CR)","description":"Complete response (CR) was defined as the disappearance of all target lesions; partial response (PR) was defined as at least a 30% decrease in sum of longest diameter of target lesions.","timeFrame":"Randomization to the first date of progressive disease (up to 12.1 months)"},{"measure":"Duration of Response","description":"Duration of response was measured from the time measurement criteria were met for complete response (CR) or partial response (PR) (whichever was first recorded) until the first date of documented progressive disease (PD) or death. Complete response (CR) was defined as the disappearance of all target lesions; PR was defined as at least a 30% decrease in sum of longest diameter of target lesions; PD was defined as at least a 20% increase in sum of longest diameter of target lesions. Duration of response was censored at the date of the last assessment or follow-up visit for responders who were still alive and had not progressed.","timeFrame":"Time of response to progressive disease (PD) (approximately 8.7 months)"},{"measure":"Lung Cancer Symptom Scale (LCSS) Average Symptom Burden Index (ASBI) on Cycle 2 Day 1","description":"The worsening of symptoms was defined as a 15-millimeter (mm) increase in any 1 symptom on the Lung Cancer Symptom Scale (LCSS). The LCSS is an assessment used to evaluate 6 major symptoms associated with lung malignancies and their effect on 3 overall symptomatic items: distress, functional activities and global quality of life. LCSS consists of 2 scales: 1 completed by the participant and 1 completed by the health care professional (which is the average symptom burden index \\[ASBI\\]). Participant-reported outcomes are assessed using 9 visual analog scales (100-mm horizontal line). Participants indicate intensity of response to the items in question (0 = lowest rating, 100 = highest rating). The LCSS total score ranges from 0 (lowest rating) to 100 (highest rating) and was defined as the mean over all 9 items. ASBI was calculated as the mean of six symptom-specific questions from the LCSS, with scores range from 0 (for best outcome) to 100 (for worst outcome).","timeFrame":"Cycle 2 Day 1"},{"measure":"Lung Cancer Symptom Scale (LCSS) Average Total Score at Cycle 2 Day 1","description":"The worsening of symptoms was defined as a 15-millimeter (mm) increase in any 1 symptom on the Lung Cancer Symptom Scale (LCSS). The LCSS is an assessment used to evaluate 6 major symptoms associated with lung malignancies and their effect on 3 overall symptomatic items: distress, functional activities and global quality of life. LCSS consists of 2 scales: 1 completed by the participant and 1 completed by the health care professional (which is the average symptom burden index \\[ASBI\\]). Participant-reported outcomes are assessed using 9 visual analog scales (100-mm horizontal line). Participants indicate intensity of response to the items in question (0 = lowest rating, 100 = highest rating). The LCSS total score ranges from 0 (lowest rating) to 100 (highest rating) and was defined as the mean over all 9 items.","timeFrame":"Cycle 2 Day 1"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants with non-small cell lung cancer with locally or advanced metastatic disease(Stage IIIB or IV at entry) not amenable to curative therapy and who have progressed after 1 line of chemotherapy\n* Measureable disease as defined by response evaluation criteria in solid tumors (RECIST) version 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\n* Must make available any existing tumor tissue from the primary biopsy\n* Participants with prior radiation may be eligible if they meet certain criteria\n* Adequate bone marrow reserve and organ functioning\n* Women must have a negative pregnancy test and must comply with a highly reliable contraceptive method during and for 6 months after the treatment period and must not be breastfeeding\n* Men must comply with a contraceptive regimen during and for 6 months after the treatment period\n\nExclusion Criteria:\n\n* Currently enrolled in or discontinued a clinical trial involving an investigational drug/device within the last 30 days. Participants may be permitted to enter treatment before the 30 day waiting period in special circumstances\n* Pregnant or breastfeeding\n* Serious concomitant systemic disorders that would compromise the safety of the participant or the participant's ability to complete the study\n* Second primary malignancy that could affect compliance with the protocol or interpretation of the study results\n* Known allergy or hypersensitivity to docetaxel, taxanes, LY2181308, oligonucleotides, or any component of the formulations\n* Participants with documented central nervous system or brain metastasis at the time of study entry\n* Pre-existing neuropathy equivalent to a common terminology criteria for adverse events(CTCAE)code greater than or equal to 2","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT- 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Los Angeles","state":"California","zip":"90048","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tampa","state":"Florida","zip":"33612","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Chicago","state":"Illinois","zip":"60612","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Detroit","state":"Michigan","zip":"48201","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Minneapolis","state":"Minnesota","zip":"55455","country":"United States","geoPoint":{"lat":44.97997,"lon":-93.26384}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lebanon","state":"New Hampshire","zip":"03756","country":"United States","geoPoint":{"lat":43.64229,"lon":-72.25176}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Charleston","state":"South Carolina","zip":"29425","country":"United States","geoPoint":{"lat":32.77632,"lon":-79.93275}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Madison","state":"Wisconsin","zip":"53705","country":"United States","geoPoint":{"lat":43.07305,"lon":-89.40123}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Brussels","zip":"1200","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Edegem","zip":"2650","country":"Belgium","geoPoint":{"lat":51.15662,"lon":4.44504}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Leuven","zip":"3000","country":"Belgium","geoPoint":{"lat":50.87959,"lon":4.70093}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Braunschweig","zip":"38114","country":"Germany","geoPoint":{"lat":52.26594,"lon":10.52673}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hamburg","zip":"22527","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hanover","zip":"30625","country":"Germany","geoPoint":{"lat":52.37052,"lon":9.73322}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Heidelberg","zip":"69126","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Karlsruhe","zip":"76137","country":"Germany","geoPoint":{"lat":49.00937,"lon":8.40444}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mannheim","zip":"68167","country":"Germany","geoPoint":{"lat":49.4891,"lon":8.46694}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Münster","zip":"48149","country":"Germany","geoPoint":{"lat":51.96236,"lon":7.62571}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ulm","zip":"89081","country":"Germany","geoPoint":{"lat":48.39841,"lon":9.99155}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Aviano","zip":"33081","country":"Italy","geoPoint":{"lat":46.07056,"lon":12.59472}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Genova","zip":"16132","country":"Italy","geoPoint":{"lat":45.21604,"lon":11.87211}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lido di Camaiore","zip":"55043","country":"Italy","geoPoint":{"lat":43.90012,"lon":10.2269}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Orbassano","zip":"10043","country":"Italy","geoPoint":{"lat":45.00547,"lon":7.53813}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Pisa","zip":"56100","country":"Italy","geoPoint":{"lat":43.70853,"lon":10.4036}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Rome","zip":"00168","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Gdansk","zip":"80-952","country":"Poland","geoPoint":{"lat":54.35227,"lon":18.64912}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Poznan","zip":"60-569","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Szczecin-Zdunowo","country":"Poland"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Warsaw","zip":"02-781","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"London","state":"England","zip":"SE1 9RT","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Nottingham","state":"Nottinghamshire","zip":"NG5 1PD","country":"United Kingdom","geoPoint":{"lat":52.9536,"lon":-1.15047}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Headington","state":"Oxford","zip":"OX3 7LJ","country":"United Kingdom","geoPoint":{"lat":51.75737,"lon":-1.21974}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Aberdeen","state":"Scotland","zip":"AB25 2ZN","country":"United Kingdom","geoPoint":{"lat":57.14369,"lon":-2.09814}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Sheffield","state":"Trent","zip":"S10 2SJ","country":"United Kingdom","geoPoint":{"lat":53.38297,"lon":-1.4659}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Manchester","zip":"M20 4BX","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}}]},"referencesModule":{"references":[{"pmid":"25436803","type":"DERIVED","citation":"Natale R, Blackhall F, Kowalski D, Ramlau R, Bepler G, Grossi F, Lerchenmuller C, Pinder-Schenck M, Mezger J, Danson S, Gadgeel SM, Summers Y, Callies S, Andre V, Das M, Lahn M, Talbot D. Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study. J Thorac Oncol. 2014 Nov;9(11):1704-8. doi: 10.1097/JTO.0000000000000285."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"timeFrame":"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.","accessCriteria":"A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.","url":"https://vivli.org/"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"LY2181308 + Docetaxel","description":"LY2181308: 750 milligrams (mg), intravenous (IV), on Day -2 and Day -1 of a 2 day lead-in period; on Day 1, Day 6, and Day 14 for Cycle 1 (1 cycle = 21 days); and once weekly for Days 1 through 21 for Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.\n\nDocetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV), on Day 1 of Cycle 1 (1 cycle = 21 days) and on Day 1 of Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."},{"id":"FG001","title":"Docetaxel","description":"Docetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV) on Day 1 of Cycles 1 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"120"},{"groupId":"FG001","numSubjects":"60"}]},{"type":"Received At Least 1 Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"114"},{"groupId":"FG001","numSubjects":"48"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"112"},{"groupId":"FG001","numSubjects":"47"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"13"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"12"}]},{"type":"Protocol Entry Criteria Not Met","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Participants who received at least 1 dose of study drug.","groups":[{"id":"BG000","title":"LY2181308 + Docetaxel","description":"LY2181308: 750 milligrams (mg), intravenous (IV), on Day -2 and Day -1 of a 2 day lead-in period; on Day 1, Day 6, and Day 14 for Cycle 1 (1 cycle = 21 days); and once weekly for Days 1 through 21 for Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.\n\nDocetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV), on Day 1 of Cycle 1 (1 cycle = 21 days) and on Day 1 of Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."},{"id":"BG001","title":"Docetaxel","description":"Docetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV) on Day 1 of Cycles 1 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"114"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"162"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"61.19","spread":"9.74"},{"groupId":"BG001","value":"64.10","spread":"8.37"},{"groupId":"BG002","value":"62.05","spread":"9.42"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"59"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"71"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"103"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"White","measurements":[{"groupId":"BG000","value":"110"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"155"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"45"}]}]},{"title":"Poland","categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"29"}]}]},{"title":"Belgium","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"5"}]}]},{"title":"Germany","categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"27"}]}]},{"title":"Italy","categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"18"}]}]},{"title":"United Kingdom","categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"38"}]}]}]},{"title":"Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)","description":"Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) classifies participants according to their functional impairment. Scores range from 0 (Fully Active), 1 (Ambulatory, restricted strenuous activity) to 5 (Death). For inclusion in this study, participants had an ECOG PS of 0 to 1.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"0","measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"50"}]},{"title":"1","measurements":[{"groupId":"BG000","value":"77"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"112"}]}]}]},{"title":"Initial pathological diagnosis","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Adenocarcinoma, poorly differentiated, lung","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Adenocarcinoma, bronchioalveolar","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"5"}]},{"title":"Adenocarcinoma, lung","measurements":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"78"}]},{"title":"Neuroendocrine carcinoma (CA)","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Large cell lung CA","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Non-small cell lung carcinoma (NSCLC)","measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"18"}]},{"title":"NSCLC, poorly differentiated","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"9"}]},{"title":"Squamous cell lung CA","measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"48"}]},{"title":"NSCLC, not otherwise specified (NOS)","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Disease stage at study entry","description":"Stage means how big the tumor is and how far it has spread. Stages range from 0 (not spread) to IV (spread throughout the body).\n\nStage IIIB - the cancer has spread to nearby tissue or spread to far away lymph nodes; Stage IV - the cancer has spread to other organs of the body such as the other lung, brain, or liver","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Stage IIIB","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"16"}]},{"title":"Stage IV","measurements":[{"groupId":"BG000","value":"104"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"146"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Tumor Size to the End of Cycle 2","description":"The tumor size was defined as the sum of the longest diameters for the target lesions. The sum of lesion diameters was calculated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines. The log ratio of tumor size at the end of Cycle 2 to tumor size at baseline was calculated for each participant.","populationDescription":"Participants who received at least 1 dose of study drug and had tumor size measurements (according to the pre-specified inclusion criteria) at baseline and at the end of Cycle 2.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Log Ratio of Tumor Size","timeFrame":"Baseline, End of Cycle 2 (1 cycle = 21 days)","groups":[{"id":"OG000","title":"LY2181308 + Docetaxel","description":"LY2181308: 750 milligrams (mg), intravenous (IV), on Day -2 and Day -1 of a 2 day lead-in period; on Day 1, Day 6, and Day 14 for Cycle 1 (1 cycle = 21 days); and once weekly for Days 1 through 21 for Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.\n\nDocetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV), on Day 1 of Cycle 1 (1 cycle = 21 days) and on Day 1 of Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."},{"id":"OG001","title":"Docetaxel","description":"Docetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV) on Day 1 of Cycles 1 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"42"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.06","spread":"0.2"},{"groupId":"OG001","value":"1.01","spread":"0.13"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.284","pValueComment":"The t-test was based on the logarithm of the ratio of tumor size at Cycle 2 to that at baseline as this measure follows a normal distribution.","statisticalMethod":"t-test, 1 sided"}]},{"type":"SECONDARY","title":"Number of Participants With Characterization of Toxicities as Defined by Common Terminology Criteria for Adverse Events (CTCAE) Coding","description":"Safety analyses included listings and/or summaries of the following:\n\n1. CTCAE for laboratory and non-laboratory parameters possibly related to study drug;\n2. CTCAE Grades 3 and 4 for laboratory and non-laboratory parameters possibly related to study drug (Grade 3 - severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care. Grade 4 - life-threatening consequences; urgent intervention indicated);\n3. Dose adjustments due to adverse events (AEs).","populationDescription":"Participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"Randomization through long-term follow up (up to 21.6 months)","groups":[{"id":"OG000","title":"LY2181308 + Docetaxel","description":"LY2181308: 750 milligrams (mg), intravenous (IV), on Day -2 and Day -1 of a 2 day lead-in period; on Day 1, Day 6, and Day 14 for Cycle 1 (1 cycle = 21 days); and once weekly for Days 1 through 21 for Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.\n\nDocetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV), on Day 1 of Cycle 1 (1 cycle = 21 days) and on Day 1 of Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."},{"id":"OG001","title":"Docetaxel","description":"Docetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV) on Day 1 of Cycles 1 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"48"}]}],"classes":[{"title":"Participants with >= 1 CTCAE","categories":[{"measurements":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"42"}]}]},{"title":"Participants with >= 1 CTCAE Grade 3 or Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"34"}]}]},{"title":"Participants with Docetaxel Dose Changes Due to AE","categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"11"}]}]},{"title":"Participants with LY2181308 Dose Changes Due to AE","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"NA","comment":"Participants in this arm of the study did not receive LY2181308."}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS)","description":"Progression Free Survival (PFS) was defined as the time from date of first dose to the first observation of disease progression or death due to any cause. PFS time was censored at the date of the last assessment visit for participants who were still alive and who did not have documented progressive disease as of the data cut-off date.","populationDescription":"Participants who received at least 1 dose of study drug. A total of 10 participants were censored in the Docetaxel arm; 18 participants were censored in the LY2181308 + Docetaxel arm.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Randomization to the first date of progressive disease or death from any cause (up to 12.88 months)","groups":[{"id":"OG000","title":"LY2181308 + Docetaxel","description":"LY2181308: 750 milligrams (mg), intravenous (IV), on Day -2 and Day -1 of a 2 day lead-in period; on Day 1, Day 6, and Day 14 for Cycle 1 (1 cycle = 21 days); and once weekly for Days 1 through 21 for Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.\n\nDocetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV), on Day 1 of Cycle 1 (1 cycle = 21 days) and on Day 1 of Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."},{"id":"OG001","title":"Docetaxel","description":"Docetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV) on Day 1 of Cycles 1 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"48"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.83","lowerLimit":"1.84","upperLimit":"3.65"},{"groupId":"OG001","value":"3.35","lowerLimit":"2.69","upperLimit":"4.57"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Area Under the Concentration Curve From Zero to 4 Hours (AUC[0-4]) for LY2181309 and Docetaxel","description":"Pharmacokinetics: Area Under the Concentration Curve From Zero to 4 hours (AUC\\[0-4\\]) for LY2181309 and Docetaxel","populationDescription":"Participants who received at least 1 dose of study drug and who had an interpretable pharmacokinetic profile","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nanograms*hours per milliliter (ng*h/mL)","timeFrame":"Docetaxel: Cycle(C)1 Day(D)1:0,1,1.25,1.75,3,4 hours(h);LY2181308 + Docetaxel: C1 D-1:3,4 h;D1:0,3,4 h","groups":[{"id":"OG000","title":"LY2181308 + Docetaxel","description":"LY2181308: 750 milligrams (mg), intravenous (IV), on Day -2 and Day -1 of a 2 day lead-in period; on Day 1, Day 6, and Day 14 for Cycle 1 (1 cycle = 21 days); and once weekly for Days 1 through 21 for Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.\n\nDocetaxel: 75 milligrams/meters squared (mg/m\\^2), intravenous (IV), on Day 1 of Cycle 1 (1 cycle = 21 days) and on Day 1 of Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."},{"id":"OG001","title":"Docetaxel","description":"Docetaxel: 75 milligrams/meters squared (mg/m\\^2), intravenous (IV) on Day 1 of Cycles 1 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"42"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1642","spread":"76.4"},{"groupId":"OG001","value":"1195","spread":"104"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Area Under the Drug Concentration-Time Curve From Zero to Infinity (AUC[0 ∞]) of LY2181309 and Docetaxel","description":"Pharmacokinetics: Area Under the Drug Concentration-Time Curve From Zero to Infinity (AUC\\[0 ∞\\]) of LY2181309 and Docetaxel","populationDescription":"Participants who received at least 1 dose of study drug and who had an interpretable pharmacokinetic profile","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nanograms*hours per milliliter (ng*h/mL)","timeFrame":"Docetaxel: Cycle(C)1 Day(D)1:0,1,1.25,1.75,3,4,5,505,513,2521 hours(h);LY2181308 + Docetaxel: C1 D -1:3,4 h;D1:0,3,4,5,5.25,5.75,7,8,120,504,507,509,1008,1512,1515,1517,2016, 2520,2523,2525 h","groups":[{"id":"OG000","title":"LY2181308 + Docetaxel","description":"LY2181308: 750 milligrams (mg), intravenous (IV), on Day -2 and Day -1 of a 2 day lead-in period; on Day 1, Day 6, and Day 14 for Cycle 1 (1 cycle = 21 days); and once weekly for Days 1 through 21 for Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.\n\nDocetaxel: 75 milligrams/meters squared (mg/m\\^2), intravenous (IV), on Day 1 of Cycle 1 (1 cycle = 21 days) and on Day 1 of Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."},{"id":"OG001","title":"Docetaxel","description":"Docetaxel: 75 milligrams/meters squared (mg/m\\^2), intravenous (IV) on Day 1 of Cycles 1 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"42"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1905","spread":"64.7"},{"groupId":"OG001","value":"1778","spread":"87.8"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"Overall survival (OS) was the duration from enrollment to death from any cause. For participants who were alive, OS is censored at the date of last contact.","populationDescription":"Participants who received at least 1 dose of study drug. A total of 20 participants were censored in the Docetaxel arm; 41 participants were censored in the LY2181308 + Docetaxel arm.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to date of death from any cause (up to 21.6 months)","groups":[{"id":"OG000","title":"LY2181308 + Docetaxel","description":"LY2181308: 750 milligrams (mg), intravenous (IV), on Day -2 and Day -1 of a 2 day lead-in period; on Day 1, Day 6, and Day 14 for Cycle 1 (1 cycle = 21 days); and once weekly for Days 1 through 21 for Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.\n\nDocetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV), on Day 1 of Cycle 1 (1 cycle = 21 days) and on Day 1 of Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."},{"id":"OG001","title":"Docetaxel","description":"Docetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV) on Day 1 of Cycles 1 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"48"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","lowerLimit":"6.6","upperLimit":"9.7"},{"groupId":"OG001","value":"8.8","lowerLimit":"5.7","upperLimit":"13.8"}]}]}]},{"type":"SECONDARY","title":"Time to Worsening of Symptoms as Defined by Lung Cancer Symptom Score (LCSS) Questionnaire","description":"The worsening of symptoms was defined as a 15-millimeter (mm) increase in any 1 symptom on the LCSS. The LCSS is an assessment used to evaluate 6 major symptoms associated with lung malignancies and their effect on overall symptomatic distress, functional activities, and global quality of life. LCSS consists of 2 scales: 1 completed by the participant and 1 completed by the health care professional (which is the average symptom burden index \\[ASBI\\]). Participant-reported outcomes are assessed using 9 visual analog scales (100-mm horizontal line). Participants indicate intensity of response to the items in question (0 = lowest rating, 100 = highest rating). The LCSS total score ranges from 0 (lowest rating) to 100 (highest rating). The LCSS total score was defined as the mean over all 9 items. Time to worsening of symptoms was censored at the date of the last assessment visit for participants who did not experience any worsening of symptoms as of the data cut-off date.","populationDescription":"Participants who received at least 1 dose of study drug. A total of 10 participants were censored in the Docetaxel arm; 26 participants were censored in the LY2181308 + Docetaxel arm.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline to the worsening of symptoms (up to 4.6 months)","groups":[{"id":"OG000","title":"LY2181308 + Docetaxel","description":"LY2181308: 750 milligrams (mg), intravenous (IV), on Day -2 and Day -1 of a 2 day lead-in period; on Day 1, Day 6, and Day 14 for Cycle 1 (1 cycle = 21 days); and once weekly for Days 1 through 21 for Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.\n\nDocetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV), on Day 1 of Cycle 1 (1 cycle = 21 days) and on Day 1 of Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."},{"id":"OG001","title":"Docetaxel","description":"Docetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV) on Day 1 of Cycles 1 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"48"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.7","upperLimit":"1.0"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.5","upperLimit":"1.1"}]}]}]},{"type":"SECONDARY","title":"Time to Objective Tumor Response of Partial Response (PR) or Complete Response (CR)","description":"Time to objective tumor response was defined as the time from the date of randomization to the first date of documented objective tumor response. Time to objective tumor response was censored at the date of the last assessment visit for participants who had not had documented response as of the data cut-off date. Complete response (CR) was defined as the disappearance of all target lesions; partial response (PR) was defined as at least a 30% decrease in sum of the longest diameter of target lesions.","populationDescription":"Participants who received at least 1 dose of study drug. A total of 47 participants were censored in the Docetaxel arm; 107 participants were censored in the LY2181308 + Docetaxel arm.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Randomization to the date of first response (up to 12.1 months)","groups":[{"id":"OG000","title":"LY2181308 + Docetaxel","description":"LY2181308: 750 milligrams (mg), intravenous (IV), on Day -2 and Day -1 of a 2 day lead-in period; on Day 1, Day 6, and Day 14 for Cycle 1 (1 cycle = 21 days); and once weekly for Days 1 through 21 for Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.\n\nDocetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV), on Day 1 of Cycle 1 (1 cycle = 21 days) and on Day 1 of Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."},{"id":"OG001","title":"Docetaxel","description":"Docetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV) on Day 1 of Cycles 1 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"48"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Due to the high rate of censored participants (107 of 114 participants), the median could not be calculated."},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Due to the high rate of censored participants (47 of 48 participants), the median could not be calculated."}]}]}]},{"type":"SECONDARY","title":"Time to Documented Disease Progression","description":"Time to documented disease progression was defined as the time from the date of randomization to the first date of documented progression. Progressive disease (PD) was defined as at least a 20% increase in sum of longest diameter of target lesions. Time to documented disease progression was censored at the date of the last assessment visit for participants who had not had documented progressive disease as of the data cut-off date.","populationDescription":"Participants who received at least 1 dose of study drug. A total of 15 participants were censored in the Docetaxel arm; 38 participants were censored in the LY2181308 + Docetaxel arm.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Randomization to the first date of progressive disease (up to 12.9 months)","groups":[{"id":"OG000","title":"LY2181308 + Docetaxel","description":"LY2181308: 750 milligrams (mg), intravenous (IV), on Day -2 and Day -1 of a 2 day lead-in period; on Day 1, Day 6, and Day 14 for Cycle 1 (1 cycle = 21 days); and once weekly for Days 1 through 21 for Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.\n\nDocetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV), on Day 1 of Cycle 1 (1 cycle = 21 days) and on Day 1 of Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."},{"id":"OG001","title":"Docetaxel","description":"Docetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV) on Day 1 of Cycles 1 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"48"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","lowerLimit":"2.0","upperLimit":"3.7"},{"groupId":"OG001","value":"3.4","lowerLimit":"2.8","upperLimit":"5.6"}]}]}]},{"type":"SECONDARY","title":"Percent of Participants Having a Partial Response (PR) or a Complete Response (CR)","description":"Complete response (CR) was defined as the disappearance of all target lesions; partial response (PR) was defined as at least a 30% decrease in sum of longest diameter of target lesions.","populationDescription":"Participants who received at least 1 dose of study drug. A total of 47 participants were censored in the Docetaxel arm; 107 participants were censored in the LY2181308 + Docetaxel arm.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Randomization to the first date of progressive disease (up to 12.1 months)","groups":[{"id":"OG000","title":"LY2181308 + Docetaxel","description":"LY2181308: 750 milligrams (mg), intravenous (IV), on Day -2 and Day -1 of a 2 day lead-in period; on Day 1, Day 6, and Day 14 for Cycle 1 (1 cycle = 21 days); and once weekly for Days 1 through 21 for Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.\n\nDocetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV), on Day 1 of Cycle 1 (1 cycle = 21 days) and on Day 1 of Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."},{"id":"OG001","title":"Docetaxel","description":"Docetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV) on Day 1 of Cycles 1 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"48"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1"},{"groupId":"OG001","value":"2.1"}]}]}]},{"type":"SECONDARY","title":"Duration of Response","description":"Duration of response was measured from the time measurement criteria were met for complete response (CR) or partial response (PR) (whichever was first recorded) until the first date of documented progressive disease (PD) or death. Complete response (CR) was defined as the disappearance of all target lesions; PR was defined as at least a 30% decrease in sum of longest diameter of target lesions; PD was defined as at least a 20% increase in sum of longest diameter of target lesions. Duration of response was censored at the date of the last assessment or follow-up visit for responders who were still alive and had not progressed.","populationDescription":"Participants who received at least 1 dose of study drug and achieved CR or PR. A total of 0 participants were censored in the Docetaxel arm; 2 participants were censored in the LY2181308 + Docetaxel arm.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Time of response to progressive disease (PD) (approximately 8.7 months)","groups":[{"id":"OG000","title":"LY2181308 + Docetaxel","description":"LY2181308: 750 milligrams (mg), intravenous (IV), on Day -2 and Day -1 of a 2 day lead-in period; on Day 1, Day 6, and Day 14 for Cycle 1 (1 cycle = 21 days); and once weekly for Days 1 through 21 for Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.\n\nDocetaxel: 75 milligrams/meters squared (mg/m\\^2), intravenous (IV), on Day 1 of Cycle 1 (1 cycle = 21 days) and on Day 1 of Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."},{"id":"OG001","title":"Docetaxel","description":"Docetaxel: 75 milligrams/meters squared (mg/m\\^2), intravenous (IV) on Day 1 of Cycles 1 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","lowerLimit":"2.8","upperLimit":"NA","comment":"The upper range of the confidence interval (CI) could not be calculated due to lack of data (5 response events, 2 participants censored)."},{"groupId":"OG001","value":"5.4","lowerLimit":"NA","upperLimit":"NA","comment":"The confidence interval (CI) could not be calculated due to lack of data (1 response event, 0 participants censored)."}]}]}]},{"type":"SECONDARY","title":"Lung Cancer Symptom Scale (LCSS) Average Symptom Burden Index (ASBI) on Cycle 2 Day 1","description":"The worsening of symptoms was defined as a 15-millimeter (mm) increase in any 1 symptom on the Lung Cancer Symptom Scale (LCSS). The LCSS is an assessment used to evaluate 6 major symptoms associated with lung malignancies and their effect on 3 overall symptomatic items: distress, functional activities and global quality of life. LCSS consists of 2 scales: 1 completed by the participant and 1 completed by the health care professional (which is the average symptom burden index \\[ASBI\\]). Participant-reported outcomes are assessed using 9 visual analog scales (100-mm horizontal line). Participants indicate intensity of response to the items in question (0 = lowest rating, 100 = highest rating). The LCSS total score ranges from 0 (lowest rating) to 100 (highest rating) and was defined as the mean over all 9 items. ASBI was calculated as the mean of six symptom-specific questions from the LCSS, with scores range from 0 (for best outcome) to 100 (for worst outcome).","populationDescription":"Participants who received at least 1 dose of study drug and had evaluable LCSS data.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"units on a scale","timeFrame":"Cycle 2 Day 1","groups":[{"id":"OG000","title":"LY2181308 + Docetaxel","description":"LY2181308: 750 milligrams (mg), intravenous (IV), on Day -2 and Day -1 of a 2 day lead-in period; on Day 1, Day 6, and Day 14 for Cycle 1 (1 cycle = 21 days); and once weekly for Days 1 through 21 for Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.\n\nDocetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV), on Day 1 of Cycle 1 (1 cycle = 21 days) and on Day 1 of Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."},{"id":"OG001","title":"Docetaxel","description":"Docetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV) on Day 1 of Cycles 1 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"38"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","lowerLimit":"11","upperLimit":"34"},{"groupId":"OG001","value":"24","lowerLimit":"15","upperLimit":"38"}]}]}]},{"type":"SECONDARY","title":"Lung Cancer Symptom Scale (LCSS) Average Total Score at Cycle 2 Day 1","description":"The worsening of symptoms was defined as a 15-millimeter (mm) increase in any 1 symptom on the Lung Cancer Symptom Scale (LCSS). The LCSS is an assessment used to evaluate 6 major symptoms associated with lung malignancies and their effect on 3 overall symptomatic items: distress, functional activities and global quality of life. LCSS consists of 2 scales: 1 completed by the participant and 1 completed by the health care professional (which is the average symptom burden index \\[ASBI\\]). Participant-reported outcomes are assessed using 9 visual analog scales (100-mm horizontal line). Participants indicate intensity of response to the items in question (0 = lowest rating, 100 = highest rating). The LCSS total score ranges from 0 (lowest rating) to 100 (highest rating) and was defined as the mean over all 9 items.","populationDescription":"Participants who received at least 1 dose of study drug and had evaluable LCSS data.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"units on a scale","timeFrame":"Cycle 2 Day 1","groups":[{"id":"OG000","title":"LY2181308 + Docetaxel","description":"LY2181308: 750 milligrams (mg), intravenous (IV), on Day -2 and Day -1 of a 2 day lead-in period; on Day 1, Day 6, and Day 14 for Cycle 1 (1 cycle = 21 days); and once weekly for Days 1 through 21 for Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.\n\nDocetaxel: 75 milligrams/meters squared (mg/m\\^2), intravenous (IV), on Day 1 of Cycle 1 (1 cycle = 21 days) and on Day 1 of Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."},{"id":"OG001","title":"Docetaxel","description":"Docetaxel: 75 milligrams/meters squared (mg/m\\^2), intravenous (IV) on Day 1 of Cycles 1 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"37"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","lowerLimit":"11","upperLimit":"38"},{"groupId":"OG001","value":"30","lowerLimit":"20","upperLimit":"41"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"LY2181308 + Docetaxel","description":"LY2181308: 750 milligrams (mg), intravenous (IV), on Day -2 and Day -1 of a 2 day lead-in period; on Day 1, Day 6, and Day 14 for Cycle 1 (1 cycle = 21 days); and once weekly for Days 1 through 21 for Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.\n\nDocetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV), on Day 1 of Cycle 1 (1 cycle = 21 days) and on Day 1 of Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.","seriousNumAffected":65,"seriousNumAtRisk":120,"otherNumAffected":106,"otherNumAtRisk":120},{"id":"EG001","title":"Docetaxel","description":"Docetaxel: 75 milligrams/square meter (mg/m\\^2), intravenous (IV) on Day 1 of Cycles 1 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.","seriousNumAffected":24,"seriousNumAtRisk":60,"otherNumAffected":44,"otherNumAtRisk":60}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":120},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":60}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":120},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":60}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":60}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Event resulted in death","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Left ventricular dysfunction","organSystem":"Cardiac disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Abdominal symptom","organSystem":"Gastrointestinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"Diverticular perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Event resulted in death","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":60}]},{"term":"Generalised oedema","organSystem":"General disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":120},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":60}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Bronchopneumonia","organSystem":"Infections and infestations","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Neutropenic infection","organSystem":"Infections and infestations","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Neutropenic sepsis","organSystem":"Infections and infestations","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":120},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":60}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":120},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":60}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Subdural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"C-reactive protein increased","organSystem":"Investigations","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Metastatic pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":60}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Acute respiratory distress syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":3,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Dyspnoea at rest","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":60}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Laryngeal haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":60}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Lymphoedema","organSystem":"Vascular disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":61,"numAffected":44,"numAtRisk":120},{"groupId":"EG001","numEvents":16,"numAffected":13,"numAtRisk":60}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":14,"numAtRisk":120},{"groupId":"EG001","numEvents":27,"numAffected":10,"numAtRisk":60}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":60}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":53,"numAffected":35,"numAtRisk":120},{"groupId":"EG001","numEvents":40,"numAffected":14,"numAtRisk":60}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":13,"numAtRisk":120},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":60}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":13,"numAtRisk":120},{"groupId":"EG001","numEvents":12,"numAffected":11,"numAtRisk":60}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":47,"numAffected":34,"numAtRisk":120},{"groupId":"EG001","numEvents":28,"numAffected":22,"numAtRisk":60}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":120},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":60}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":51,"numAffected":35,"numAtRisk":120},{"groupId":"EG001","numEvents":14,"numAffected":12,"numAtRisk":60}]},{"term":"Oral pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":60}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":120},{"groupId":"EG001","numEvents":12,"numAffected":4,"numAtRisk":60}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":23,"numAtRisk":120},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":60}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":120},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":60}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":11,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":70,"numAffected":53,"numAtRisk":120},{"groupId":"EG001","numEvents":32,"numAffected":24,"numAtRisk":60}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":8,"numAtRisk":120},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":60}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":13,"numAtRisk":120},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":60}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":60}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":26,"numAtRisk":120},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":60}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":120},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":60}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":24,"numAtRisk":120},{"groupId":"EG001","numEvents":14,"numAffected":12,"numAtRisk":60}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":120},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":60}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":120},{"groupId":"EG001","numEvents":7,"numAffected":4,"numAtRisk":60}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":120},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":60}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":9,"numAtRisk":120},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":60}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":120},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":60}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":60}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":9,"numAtRisk":120},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":60}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":120},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":60}]},{"term":"Ageusia","organSystem":"Nervous system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":60}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":120},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":60}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":120},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":60}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":120},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":60}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":120},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":60}]},{"term":"Polyneuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":60}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":120},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":60}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":15,"numAtRisk":120},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":60}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":24,"numAtRisk":120},{"groupId":"EG001","numEvents":13,"numAffected":12,"numAtRisk":60}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":120},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":60}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":120},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":60}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":60}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":33,"numAtRisk":120},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":60}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":120},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":60}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","email":"ClinicalTrials.gov@lilly.com","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077143","term":"Docetaxel"},{"id":"C529350","term":"LY 2181308"}],"ancestors":[{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"}]}},"hasResults":true}